Etoricoxib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) and PHARMAC (New Zealand) recommended or restricted etoricoxib, while AWMSG (Wales) did not recommend it.
The file has been open for more than a decade: 12.1 years separate the first record, 7 Mar 2003 at SMC (Scotland), from the most recent, 1 Apr 2015 at HAS (France).
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for etoricoxib, 2 submissions were never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2015; on this evidence the file is dormant.
5 distinct indication wordings are recorded for etoricoxib by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess etoricoxib, on 7 Mar 2003; PHARMAC (New Zealand) did not open a file until 14 Aug 2014 — an unusually long tail of 11.4 years between the earliest and latest system to look at it.
3 of the 4 agencies here assessed etoricoxib more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed etoricoxib.
The full ledger for etoricoxib reads 3 other, 2 non-submission, 2 not assessed and 1 recommended, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 1 Apr 2015 | Listing renewal (Transparency Committee) | SMR moderate | source |
| PHARMAC (New Zealand) | 14 Aug 2014 | Osteoarthritis and rheumatoid arthritis | PTAC advice: Low · decision reached | source |
| SMC (Scotland) | 14 Jan 2013 | short-term treatment of moderate pain associated with dental surgery. | not recommended | source |
| AWMSG (Wales) | 25 Oct 2012 | Short-term treatment of moderate pain associated with dental surgery | not endorsed (non-submission) | source |
| AWMSG (Wales) | 24 Sep 2009 | Symptomatic relief of ankylosing spondylitis | outside AWMSG criteria | source |
5 further decisions for etoricoxib, across 3 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- ibuprofen — same ATC class M01A — Anti-inflammatories and antirheumatics
- busulfan — also decided by HAS in 2015Q2
- pasireotide — also decided by HAS in 2015Q2
- omalizumab — also decided by HAS in 2015Q2
- sorafenib — also decided by HAS in 2015Q2
- bevacizumab — also decided by HAS in 2015Q2
Coverage: 10 decisions for etoricoxib from 4 agencies, 2003 to 2015. Data to 7 Sep 2026. ATC class M01A — Anti-inflammatories and antirheumatics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.